FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136267457> ?p ?o ?g. }

• W3136267457 endingPage "155498" @default.
• W3136267457 startingPage "155498" @default.
• W3136267457 abstract "Activation of CXCR2 by chemokines such as CXCL1 and CXCL2 increases aggressiveness of breast cancer, inducing chemoresistance, hence CXCR2 antagonists are in clinical trials. We previously reported that inhibition of CXCR2 increases MIP-2 (CXCL2), which may inhibit anti-tumoral effects of CXCR2 antagonists. This seems to be due to inhibition of protein kinase C (PKC) by CXCR2 antagonist since specific inhibitor of PKC also enhances MIP-2 secretion. We here examined whether CXCR2 inhibitor also increases KC (CXCL1) secretion, ligand for CXCR2 involved in metastasis and PKC activators can prevent increases in chemokine secretion. We used SB 225002, which is a specific CXCR2 antagonist. The effects of PKC activators that have documented anti-tumoral effects and activates multiple isozymes of PKC such as Ingenol-3-angelate (I3A) and bryostatin-1 were examined here. In addition, FR236924, PKCε selective and 7α-acetoxy-6β-benzoyloxy-12-O-benzoylroyleanone (Roy-Bz), PKCδ selective activators were also tested. The effects of activators were determined using brain metastatic (4TBM) and heart metastatic (4THM) subset of 4T1 breast carcinoma cells because these aggressive carcinoma cells with cancer stem cell features secrete high levels of KC and MIP-2. Inhibition of CXCR-2 activity increased KC (CXCL1) secretion. PKC activators prevented SB225002-induced increases in KC and MIP-2 secretion. Different activators/modulators induce differential changes in basal and SB225002-induced chemokine secretion as well as cell proliferation and the activators that act on PKCδ and/or PKCε such as bryostatin 1, FR236924 and Roy-Bz are the most effective. These activators alone also decrease cell proliferation or chemokine secretion or both. Given the role of KC and MIP-2 in drug resistance including chemotherapeutics, activators of PKCε and PKCδ may prevent emerging of resistance to CXCR2 inhibitors as well as other chemotherapeutics." @default.
• W3136267457 created "2021-03-29" @default.
• W3136267457 creator A5012111165 @default.
• W3136267457 creator A5048580605 @default.
• W3136267457 creator A5059788934 @default.
• W3136267457 creator A5060834365 @default.
• W3136267457 creator A5086346482 @default.
• W3136267457 date "2021-06-01" @default.
• W3136267457 modified "2023-09-24" @default.
• W3136267457 title "Rebound increases in chemokines by CXCR2 antagonist in breast cancer can be prevented by PKCδ and PKCε activators" @default.
• W3136267457 cites W1493948383 @default.
• W3136267457 cites W1548282268 @default.
• W3136267457 cites W1592707856 @default.
• W3136267457 cites W1637945960 @default.
• W3136267457 cites W1847993443 @default.
• W3136267457 cites W1911093385 @default.
• W3136267457 cites W1980814667 @default.
• W3136267457 cites W1993077931 @default.
• W3136267457 cites W1996339149 @default.
• W3136267457 cites W2000542448 @default.
• W3136267457 cites W2005400238 @default.
• W3136267457 cites W2006020460 @default.
• W3136267457 cites W2009600715 @default.
• W3136267457 cites W2013913223 @default.
• W3136267457 cites W2014708931 @default.
• W3136267457 cites W2016861424 @default.
• W3136267457 cites W2030515873 @default.
• W3136267457 cites W2035442827 @default.
• W3136267457 cites W2041795317 @default.
• W3136267457 cites W2051144159 @default.
• W3136267457 cites W2060634714 @default.
• W3136267457 cites W2067508471 @default.
• W3136267457 cites W2069539795 @default.
• W3136267457 cites W2069723308 @default.
• W3136267457 cites W2070099778 @default.
• W3136267457 cites W2071856972 @default.
• W3136267457 cites W2072531648 @default.
• W3136267457 cites W2077072914 @default.
• W3136267457 cites W2080790098 @default.
• W3136267457 cites W2085642575 @default.
• W3136267457 cites W2087517352 @default.
• W3136267457 cites W2093904239 @default.
• W3136267457 cites W2096216039 @default.
• W3136267457 cites W2103235619 @default.
• W3136267457 cites W2119098545 @default.
• W3136267457 cites W2121955821 @default.
• W3136267457 cites W2139992970 @default.
• W3136267457 cites W2151832198 @default.
• W3136267457 cites W2161407210 @default.
• W3136267457 cites W2188769365 @default.
• W3136267457 cites W2235860151 @default.
• W3136267457 cites W2376006428 @default.
• W3136267457 cites W2610191231 @default.
• W3136267457 cites W2611128115 @default.
• W3136267457 cites W2619223301 @default.
• W3136267457 cites W2757364581 @default.
• W3136267457 cites W2785141812 @default.
• W3136267457 cites W2791212110 @default.
• W3136267457 cites W2802566020 @default.
• W3136267457 cites W2889051661 @default.
• W3136267457 cites W2966200870 @default.
• W3136267457 cites W2982238859 @default.
• W3136267457 cites W2994091419 @default.
• W3136267457 cites W3013245743 @default.
• W3136267457 cites W3035838036 @default.
• W3136267457 doi "https://doi.org/10.1016/j.cyto.2021.155498" @default.
• W3136267457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33773907" @default.
• W3136267457 hasPublicationYear "2021" @default.
• W3136267457 type Work @default.
• W3136267457 sameAs 3136267457 @default.
• W3136267457 citedByCount "4" @default.
• W3136267457 countsByYear W31362674572021 @default.
• W3136267457 countsByYear W31362674572022 @default.
• W3136267457 crossrefType "journal-article" @default.
• W3136267457 hasAuthorship W3136267457A5012111165 @default.
• W3136267457 hasAuthorship W3136267457A5048580605 @default.
• W3136267457 hasAuthorship W3136267457A5059788934 @default.
• W3136267457 hasAuthorship W3136267457A5060834365 @default.
• W3136267457 hasAuthorship W3136267457A5086346482 @default.
• W3136267457 hasConcept C126322002 @default.
• W3136267457 hasConcept C12823836 @default.
• W3136267457 hasConcept C13373296 @default.
• W3136267457 hasConcept C134018914 @default.
• W3136267457 hasConcept C170493617 @default.
• W3136267457 hasConcept C179661763 @default.
• W3136267457 hasConcept C185592680 @default.
• W3136267457 hasConcept C195794163 @default.
• W3136267457 hasConcept C2910806222 @default.
• W3136267457 hasConcept C49039625 @default.
• W3136267457 hasConcept C502942594 @default.
• W3136267457 hasConcept C62478195 @default.
• W3136267457 hasConcept C71924100 @default.
• W3136267457 hasConcept C84913492 @default.
• W3136267457 hasConcept C86803240 @default.
• W3136267457 hasConcept C95444343 @default.
• W3136267457 hasConcept C96525457 @default.
• W3136267457 hasConcept C98274493 @default.
• W3136267457 hasConceptScore W3136267457C126322002 @default.

• next